Predictive effect of serum CDH13 methylation for progression after TURBT in patients with non-muscle invasive bladder cancer
10.3969/j.issn.1671-8348.2017.35.016
- VernacularTitle:血清CDH13甲基化对非肌层浸润性膀胱癌行TURBT治疗后进展的预测作用
- Author:
Yingli LING
1
;
Yanli LI
;
Jingguang QI
;
Jie LIANG
;
Yan ZHAO
Author Information
1. 徐州市肿瘤医院泌尿外科
- Keywords:
urinary bladder neoplasms;
progression;
CDH13;
methylation
- From:
Chongqing Medicine
2017;46(35):4949-4951
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the predictive effect of serum CDH13 methylation for the progression after TURBT in the patients with non-muscle invasive bladder cancer.Methods Ninety-eight patients with non-muscle invasive bladder cancer treated by TURBT in this hospital from January 2010 to January 2012 were selected.The methylation specific PCR was used to detect the methylation status of serum CDH13.Then its correlation with the clinicopathological data as well as postoperative progression situation was analyzed.Results Serum CDH13 methylation was detected in 52 cases (53.1％),moreover serum CDH13 methylation was closely correlated with tumor size,grade and number (P＜0.05).During follow-up,20 cases (20.4％) appeared the tumor progression.The Kaplan-Meier analysis and log-rank test found that the patients with serum CDH13 methylation had shorter progression-free survival rate than the patients without serum CDH13 methylation,and the difference was statistically significant (P=0.007).The Cox regression analysis showed that serum CDH13 methylation was an independent risk factor for the progression after TURBT in non-muscle invasive bladder cancer.Conclusion Serum CDH13 methylation can serve as a predictive indicator of the progression after TURBT in non-muscle invasive bladder cancer.
